Sector News

Sobi appoints Norbert Oppitz SVP, speciality care

October 20, 2017
Life sciences

Rare diseases healthcare company Swedish Orphan Biovitrum (Sobi) has appointed Norbert Oppitz as its senior vice president for its newly established business area speciality care.

Oppitz has over 30 years’ pharmaceutical and healthcare experience and was most recently a member of the executive committee of BSN Medical in charge of its Latin America business.

In previous capacities, he has led organisations as head of Latin America at Takeda as well as in country management roles at Roche and Aventis Pharma.

He said: “I am excited to join Sobi and I look forward to contributing to the future growth of the company by realising a strategy to build and develop a strong and vital speciality care business unit.”

The new role will see Oppitz work with corporate development and the regional and country organisations.

Guido Oelkers, president and CEO of Sobi, said: “We are delighted that Norbert could join Sobi, he is a true entrepreneur and his experience will be instrumental in realising our ambitions to bring Sobi to the next level as we look for external growth opportunities for our speciality care business.”

Source: PMLive

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.